Inactive Instrument

Reunion Neuroscience

FTRP

CA76134G1037

Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer

January 18, 2023 at 07:30 am EST

Reunion Neuroscience Inc. announced that it has appointed Robert Alexander, M.D. as the Company's Chief Medical Officer, effective immediately. Dr. Alexander will report to Greg Mayes, Reunion's President and CEO. Dr. Alexander previously served as Vice President and Head, Clinical Science, in the Neuroscience Therapeutic Area Unit at Takeda Pharmaceuticals, managing all clinical trials in neuroscience from Phase 1 through 3. Prior to Takeda, Dr. Alexander served as Chief Medical Officer, BioTherapeutics, at Pfizer, directing clinical pharmacology and statistics groups while simultaneously holding the position of Vice President and Head of the Clinical Neuroscience and Pain Research Unit at the company.

Dr. Alexander also held various other senior leadership roles at AstraZeneca, GlaxoSmithKline (GSK) and Merck & Co and received his M.D. degree from The University of Chicago Pritzker School of Medicine. He is certified by the American Board of Psychiatry and Neurology and specializes in psychopharmacology, having conducted or supervised clinical studies in a broad range of neurologic and psychiatric indications.

Latest news about Reunion Neuroscience

Reunion Neuroscience Inc. Announces Advancing RE104, Its Proprietary, Clinical-Stage Serotonergic Psychedelic Drug Candidate to Provide Benefits to Patients with Underserved Mental Health Disorders	May. 02	CI
Reunion Neuroscience Inc. announced that it has received $103 million in funding from a group of investors	May. 01	CI
Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate A Phase 2 Study of Re104 for the Treatment of Postpartum Depression	23-09-18	CI
Reunion Neuroscience Brief: Reunion and MPM BioImpact Complete Plan of Arrangement Effective Today, whereby MPM Acquired Reunion in an all-cash transaction valued at Near US$13.1 million	23-08-01	MT
Reunion Neuroscience Inc.(NasdaqGS:REUN) dropped from NASDAQ Composite Index	23-08-01	CI
MPM Asset Management, L.L.C. acquired Reunion Neuroscience Inc. in a going private transaction.	23-07-31	CI
Reunion Neuroscience Gets Ontario Court's Final Approval for Acquisition by MPM BioImpact	23-07-14	MT
Reunion Neuroscience Brief: Adds In "Assuming Remaining Conditions Precedent Are Satisfied Or Waived", Anticipates Closing of Arrangement Will Occur On Or About July 21, 2023	23-07-14	MT
Reunion Neuroscience Brief: Says Obtained Final Court Order for Proposed Plan of Arrangement Whereby Affiliates of MPM BioImpact Will Buy REUN In An All-cash Deal Valued at Near US$13.1 Million	23-07-14	MT
Reunion Neuroscience Brief: Arrangement remains subject to receipt of a final order of the Ontario Superior Court of Justice (Commercial List); Expected to be completed on or around July 21, 2023	23-07-13	MT
Reunion Neuroscience Brief: Shareholders Approve Proposed Plan of Arrangement Whereby Affiliates of MPM BioImpact Will Buy REUN In An All-cash Tansaction Valued at Near US$13.1 Million	23-07-13	MT
Reunion Reports Q4 Results; Shareholders to Get US$1.12 Cash Per Share From Arrangement Agreement with MPM BioImpact	23-06-29	MT
Reunion Neuroscience Brief: Adds It Presented "Encouraging" Phase 1 Final Analysis at American Society of Clinical Psychopharmacology Annual Meeting	23-06-29	MT
Reunion Neuroscience Brief: Common Holders to Receive Consideration of US$1.12 Per Share in Cash from Arrangement Agreement with MPM BioImpact; Special Shareholder Meeting Scheduled July 12	23-06-29	MT
Reunion Neuroscience Brief: Says incurred a net loss from continuing operations of $6.5 million or $0.56 per share and $38.1 million or $3.28 per share for the three and 12 month periods ended March 31, 2023	23-06-29	MT
Reunion Neuroscience Brief: Says Rcognized a net loss from discontinued operations of $10.4 million for the 12 month period ended March 31, 2023; Adds No such loss was incurred during the three month period ended March	23-06-29	MT
Reunion Neuroscience Inc. Auditor Raises 'Going Concern' Doubt	23-06-27	CI
Reunion Neuroscience Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-06-27	CI
Reunion Neuroscience Up More Than 50% In US Pre-Market After Announcing US$13.1 Million Take-Private Transaction with MPM BioImpact	23-06-01	MT
Reunion Neuroscience Brief: Up 60% In US Pre-Market After Announcing US$13.1 Million Take-Private Transaction with MPM BioImpact; Reunion Common Holders to Get Consideration of US$1.12 Per Share in Cash	23-06-01	MT
Reunion Neuroscience Brief: Says Presented 'Encouraging" Phase 1 Final Analysis at American Society of Clinical Psychopharmacology Annual Meeting, Enabling Advancement into Phase 2 in 2H 2023	23-06-01	MT
Reunion Neuroscience Brief: Represents a 43.1% Premium to the 30-Day Volume Weighted Average Price	23-06-01	MT
Reunion Neuroscience Brief: Common Shareholders to Receive Consideration of US$1.12 Per Share in Cash	23-06-01	MT
Reunion Neuroscience Brief: Announcing US$13.1 Million Take-Private Transaction with MPM BioImpact	23-06-01	MT
MPM Asset Management, L.L.C. entered into a definitive arrangement agreement to acquire Reunion Neuroscience Inc. for CAD 17.8 million in a going private transaction.	23-05-31	CI

Chart Reunion Neuroscience

Duration

Period

More charts

Company Profile

Reunion Neuroscience Inc. is engaged in the psychedelic drug development company that provides therapeutic solutions for mental health conditions by developing serotonin receptor agonist compounds. The Company is developing the advancement of synthetic molecules targeting serotonin 5HT2A receptors. The Company's products include RE104 and RE200. The Company's lead asset, RE-104, which is a psychedelic drug being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant with durable efficacy. The RE104 as a potentially fast-acting treatment for the key indications of postpartum and treatment resistant depression. The Company is developing the RE200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psych activity for potential use in more chronic treatment paradigms and indications. The Company is focused on the research and development of its RE200 molecule group.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+38.84%	705B
NOVO NORDISK A/S	+32.24%	583B
JOHNSON & JOHNSON	-2.75%	364B
MERCK & CO., INC.	+21.24%	332B
ABBVIE INC.	+6.40%	291B
ASTRAZENECA PLC	+15.90%	238B
ROCHE HOLDING AG	-3.56%	210B
NOVARTIS AG	+10.49%	209B
AMGEN INC.	+9.79%	169B

Other Pharmaceuticals